Skip to content

Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor Engineered T cells in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Safety and efficacy of chimeric antigen receptor engineered T cells for treating relapsed or refractory leukemia and lymphoma

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031868
Enrollment
Unknown
Registered
2020-04-12
Start date
2023-08-01
Completion date
Unknown
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B cell leukemia and lymhpoma

Interventions

Case series:CART therapy

Sponsors

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
3 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Refractory or relapsed CD19 positive leukemia or lymphoma; 2. Aged 3 to 70 years; 3. ECOG score =55%; 6. Adequate liver function with AST <=5 ULN, ALT <=5 ULN; 7. Adequate kidney function with Scr<=1.6 mg/dl, BUN<=1.5 mg/dl; 8. Voluntary to enroll with signed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or nursing female patients; 2. Patients with infectious or viral diseases (HIV positive, syphilis, hepatitis b or c, etc.); 3. Patients undergoing treatment with Glucocorticoid; 4. Patients with allogeneic hematopoietic stem cell transplantation; 5. Patients undergoing with treatment against GVHD; 6. Patients with metastasis into CNS; 7. PLT<=50x10^9/L or Neutrophil<=750x10^6/L irrelevant to primary disease; 8. Patients received systemic chemotherapy 2 weeks or chemotherapy 3 weeks before blood collection.

Design outcomes

Primary

MeasureTime frame
Partial or complete remission;

Countries

China

Contacts

Public ContactXingbing Wang

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

wangxingbing@ustc.edu.cn+86 13856007984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026